An interventional study of RAS blocker tapering group and Beta blocker tapering out in Heart Failure, Ejection Fraction and Recovery of Function, sponsored by Chungnam National University Hospital. Recruiting at 2 sites in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Chungnam National University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 148 studies in Heart Failure with a site in Korea, Republic of — 48 open to participants now, 54 under way, 12 of them phase 3. Heart Failure · Korea, Republic of.
Among the 148 studies in Heart Failure with a site in Korea, Republic of, this one is the 66th largest by planned enrollment of the 109 interventional ones that give a count, is one of 15 that started in 2025, is one of 33 with no phase, reaches primary completion later than 3 of the 53 other live ones, and was the 112th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →48 of the 148 studies in Heart Failure with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Inha University Hospital · Sites in Korea, Republic of
Ages 19+
Oslo University Hospital · Sites in Korea, Republic of, United States, Belgium and 7 more countries
Ages 18+
AstraZeneca · Sites in Korea, Republic of, United States, Argentina and 29 more countries
Ages 18+
Keimyung University Dongsan Medical Center · Sites in Korea, Republic of
Ages 19+
Kyungsub Song · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
148 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 16 · Phase 3 40 · Phase 4 15
First in 1983; this study’s year is marked. 15 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 227 across the 109 interventional studies, 815 across the 39 observational. Of the 73 that completed or were terminated, 39 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
83 of 148 have an industry lead sponsor. The 10 most frequent:
Chungnam National University Hospital is the lead sponsor of 22 studies on the registry; 13 are open to participants now.
Chungnam National University Hospital has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
13 of the studies in Heart Failure with a site in Korea, Republic of that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
| NCT07111585Gachon University Gil Medical CenterPersonalized Health Coaching for Patients With HF | 2026-12 |
| NCT06122779Bristol-Myers SquibbStudy to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) | 2026-12-14 |
| NCT07379840BayerA Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South Korea | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 148 studies in Heart Failure with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study start date is on Nov 27th 2024.
A patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug tapering group ( RAS blocker or beta blocker) or continuing medication group.
Patients described above randomly assigned to drug tapering group and drug maintaining group.
Drug tapering group is 2 groups, which one is RAS blocker tapering group and others is beta blocker tapering group.
Drug tapering group is monitored ejection fraction, LV dimension and LV GLS by 1-3 month.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
NTprobnp criteria
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RAS blocker tapering
Drug: RAS blocker tapering group · Drug: Beta blocker tapering out
Beta blocker tapering arm
Drug maintain group
RAS blocker tapering out
Beta blocker tapering out group
Heart failure relapse
LVEF 10% drop, EF less than 50 %, LVIDd/BSA 10% increase, over 33mm/m\^2
Time frame: From enrollment to the end of treatment at 18 months
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Beginning 3 months after the publication of results with no end date
No publications or documents are linked to this record.
Ran from Mar 2025 to primary completion in May 2025, 2 months.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's 2 months is below that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chungnam National University Hospital